艾伯维（AbbVie）于周五表示，因其新免疫药Skyrizi和Rinvoq的销售强劲，已上调2025年利润预测，公司第一季度的业绩超过华尔街预期。公司指出，更新的预测并未考虑任何贸易政策变化，包括可能针对制药行业的美国关税。

AbbVie gave investors reason to cheer, reporting higher earnings than expected for a fifth straight quarter and raising its ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The ...

AbbVie (ABBV) stock gains as the company lifts 2025 earnings outlook after strong Q1 results, driven by its newer immunology ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

Two A+ stocks investors should consider are Alphabet (GOOG) and AbbVie (ABBV). Alphabet is the top mega-cap stock. It posted ...

AbbVie raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take ...

艾伯维公司2025年第一季度业绩超过分析师预期，每股收益为2.46美元，而预期为2.39美元，这代表约2.9%的正面惊喜。133亿美元的收入也超过了129.3亿美元的预期，凸显了公司强劲的市场表现。

周一，美国生物制药巨头艾伯维（AbbVie, NYSE: ABBV）延续了财报发布后的上涨态势，股价单日涨幅超3%，大幅跑赢标普500指数同期不足0.1%的微弱涨幅。市场分析认为，这波行情主要源于两家机构同日发布的积极研报。

The analyst continues to be positive on AbbVie, as he maintained his outperform ... the pair of drugs offset the anticipated declines of Humira. Seigerman was also cheered by what he considered ...